Original articleImmunosuppressive Drug Discontinuation in Noninfectious Uveitis From Real-Life Clinical Practice: A Survival Analysis
Section snippets
Methods
We performed a longitudinal retrospective cohort study, with subjects included between October 1989 and November 2015 and followed up until December 31, 2015, with a maximum follow-up time of 26 years. Patients were collected from the Hospital Clinico San Carlos Uveitis Clinic (HCSC-UC), a tertiary eye referral center in Madrid (Spain), composed of a multidisciplinary team of ophthalmologists and rheumatologists17 (Supplementary Text, Setting Description; Supplemental Material available at //AJO.com
Cohort Description
We identified 145 patients treated with ISDs between 1989 and 2015. We excluded 10 patients diagnosed with other inflammatory eye diseases; 8 patients treated with ISDs owing to extraocular manifestations; and 17 patients lacking information regarding dates of prescription or discontinuation. We included in our study 110 patients, with a total follow-up time of 665.2 patient-years and a median (IQR) follow-up time per patient of 4.4 years (2.5–9.1). Demographic and clinical characteristics are
Discussion
We have described the crude DRs for ISDs in a tertiary care uveitis clinic, including patients followed up to 26 years. Clinical efficacy was the most frequent cause for discontinuation, followed by inefficacy and ADRs. When analyzed by ISD, anti-TNFs and AZA exhibited the highest crude rates of discontinuation, while CSA and MTX exhibited the lowest. When analyzed by the particular ISD or combination prescribed and after adjustment for several demographic and clinical variables, we observed
References (22)
- et al.
Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study
Ophthalmology
(2004) - et al.
Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel
Am J Ophthalmol
(2000) - et al.
Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet's disease
Lancet
(1989) - et al.
Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis
Am J Ophthalmol
(1991) - et al.
Cyclosporine for ocular inflammatory diseases
Ophthalmology
(2010) - et al.
Azathioprine for ocular inflammatory diseases
Am J Ophthalmol
(2009) - et al.
Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients
Ophthalmology
(2001) - et al.
Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation
Ophthalmology
(2008) - et al.
Outcomes of changing immunosuppressive therapy after treatment failure in patients with noninfectious uveitis
Ophthalmology
(2014) - et al.
Uveitis: a potentially blinding disease
Ophthalmologica
(2004)
Causes and frequency of blindness in patients with intraocular inflammatory disease
Br J Ophthalmol
Cited by (0)
Supplemental Material available at AJO.com.